Type 2 Diabetes
Researchers analyzed how improvements in metabolic syndrome may impact the risk of developing type 2 diabetes and cardiovascular disease in patients with prediabetes.
For patients with severe obesity and type 2 diabetes, bariatric surgery is associated with a lower risk for macrovascular outcomes compared with not undergoing surgery.
A growing body of research highlights the important role of bone in glucose metabolism.
Medically supervised, therapeutic fasting regimens can help reverse type 2 diabetes (T2D) and minimize the need for pharmacological interventions.
Quick Take: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trialOctober 16, 2018
Glucagon-like peptide-1 (GLP-1) potentiates the release of insulin from pancreatic beta cells in a glucose-dependent manner.
WHO guidelines recommend selecting sulfonylureas as the single best second-line agent for Type 2 Diabetes Mellitus (T2DM) patients.
Quick Take: Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomized, placebo-controlled trialOctober 16, 2018
There is a strong relationship between body weight and the risk of developing diabetes.
Among U.S. women, a normally high circulating prolactin concentration is associated with a reduced risk for type 2 diabetes.
Greater variation of fasting plasma glucose over time is associated with an increased risk of developing type 2 diabetes.
Osteoarthritis was the most common form of arthritis in patients with diabetes but rheumatoid arthritis had the most pronounced association with diabetes.
Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.
For patients with type 2 diabetes and existing cardiovascular disease, albiglutide results in fewer cardiovascular events.
For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.
Risk for type 2 diabetes, ischemic heart disease, and peripheral vascular disease was elevated among patients with psoriatic arthritis compared with the general population.
For patients with type 2 diabetes and acute coronary syndrome, lixisenatide can slow or prevent damage to the kidneys.
In this new analysis, researchers looked at the long-term effects of the drug on diabetes prevention and remission in these patients.
Recommendations in the report highlight the importance of patient-centered decision making for glycemic management and improving diet and exercise for patients with T2D.
Obesity is associated with loss of disease-free years irrespective of position in the social hierarchy and lifestyle.
Standard pen needles have an outer cover and removable inner needle cover, while safety pen needles have an outer cover and a fixed inner needle shield that is not removed before an injection.
Combination therapies of basal insulin with either vildagliptin or lixisenatide are similarly effective at producing glycemic control improvements.
Clusters of type 2 diabetes loci and traits have been identified.
Findings from the study showed a graded association between shorter average sleep duration and higher HbA1c concentrations among participants with diabetes.
Substituting processed red meat with poultry or fish and replacing total red meat with fish were associated with a lowered risk for type 2 diabetes.
Compared with the general population, patients with type 2 diabetes are at a 35% to 60% greater risk for atrial fibrillation.
Continuous positive airway pressure for obstructive sleep apnea in patients with type 2 diabetes offered no improvement in visual acuity compared with usual care alone.
Investigators examined the effects of insulin glargine 300 U/mL vs insulin glargine 100 U/mL on glycated hemoglobin, hypoglycemia, and body weight change.
Investigators assessed the time in range according to a continuous glucose monitor and the risk for diabetic retinopathy.
Researchers aimed to determine whether variations in phosphocreatine recovery rates were marked by distinct epigenomic muscle profiles that could be seen prior to training.
Investigators examined patient factors that affect the use of diabetes medication in patients with type 2 diabetes.
SGLT-2i exhibited superior effects in terms of weight loss and did not increase the risk for hypoglycemia in dual therapy with sulfonylurea.
Endocrinology Advisor Articles
- Heritability of BMI Stronger in Obesogenic Environments
- Maternal Gluten Intake Associated With Risk for Type 1 Diabetes in Offspring
- Bone-Derived Factors in the Treatment of Diabetes
- Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy
- Thyroid Hormone Therapy Not Beneficial for Subclinical Hypothyroidism
- Bacillus Calmette-Guerin Vaccination Lowers HbA1c in Type 1 Diabetes
- Early Manifestations, Sex Differences May Aid in Acromegaly Diagnosis
- Predictive Variables for Permanent vs Transient Congenital Hypothyroidism
- Aetna-CVS Merger Approved
- The Progression of Health Care From Personalized Medicine to Wellness Genomics and Beyond